Actuate Therapeutics (ACTU) Institutional Ownership $8.28 -0.25 (-2.87%) As of 12:59 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Ownership Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsTrendsBuy This Stock Institutional Ownership Changes (13F Filings) for Actuate Therapeutics (NASDAQ:ACTU)Number ofInstitutional Buyers(last 12 months)16TotalInstitutional Inflows(last 12 months)$83.10MNumber ofInstitutional Sellers(last 12 months)0 Get ACTU Insider Trade Alerts Want to know when executives and insiders are buying or selling Actuate Therapeutics stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily. Email Address Skip Chart & View Institutional Buying and Selling Data ACTU Institutional Buying and Selling by Quarter Actuate Therapeutics Major Shareholders & Ownership History Export to ExcelReporting DateMajor Shareholder NameShares HeldMarket Value% of PortfolioQuarterly Change in SharesOwnership in CompanyDetails8/14/2025Voss Capital LP286,140$1.75M0.1%+101.0%1.398% 8/13/2025New York State Common Retirement Fund17,200$105K0.0%N/A0.084% 8/13/2025Northwestern Mutual Wealth Management Co.18,518$113K0.0%+492.6%0.090% 8/12/2025 BIOS Capital Management LP9,965,079$60.89M83.9%+0.7%48.681% 8/12/2025 Sfmg LLC14,550$89K0.0%+32.3%0.071% 8/8/2025 Geode Capital Management LLC118,050$721K0.0%+252.5%0.577% 7/17/2025 Gleason Group Inc.19,028$116K0.0%N/A0.097% 6/27/2025Goldman Sachs Group Inc.22,358$151K0.0%+98.7%0.114% 5/16/2025Goldman Sachs Group Inc.22,358$151K0.0%+98.7%0.114% 5/14/2025Voss Capital LP142,381$964K0.1%+157.7%0.729% 5/9/2025 Chicago Partners Investment Group LLC10,365$70K0.0%N/A0.053% 5/9/2025 Sfmg LLC11,000$74K0.0%N/A0.056% 5/2/2025 Sigma Planning Corp23,675$160K0.0%+47.3%0.121% 2/17/2025OMERS ADMINISTRATION Corp10,583$84K0.0%N/A0.054% 2/14/2025Mercer Global Advisors Inc. ADV16,344$130K0.0%N/A0.084% 2/14/2025Voss Capital LP55,246$440K0.0%N/A0.283% 2/13/2025 Envestnet Asset Management Inc.10,465$83K0.0%N/A0.054% 2/10/2025 BIOS Capital Management LP9,893,651$78.75M83.7%N/A50.659% 2/6/2025 Freestone Capital Holdings LLC10,000$80K0.0%N/A0.051% 2/3/2025 Sigma Planning Corp16,075$128K0.0%N/A0.082% 11/12/2024 Northwestern University27,778$207K0.2%N/A0.142% 10/29/2024 KG&L Capital Management LLC12,000$89K0.0%N/A0.061% (Data available from 1/1/2016 forward) ACTU Institutional Ownership - Frequently Asked Questions Who are the largest shareholders of ACTU shares? During the previous two years, 16 institutional investors and hedge funds held shares of Actuate Therapeutics. The most heavily invested institutionals were BIOS Capital Management LP ($60.89M), Voss Capital LP ($1.75M), Geode Capital Management LLC ($721K), Northwestern University ($207K), Sigma Planning Corp ($160K), Goldman Sachs Group Inc. ($151K), and Mercer Global Advisors Inc. ADV ($130K).Learn more on Actuate Therapeutics' institutional investors. Which institutional investors have been buying Actuate Therapeutics' stock? Of the 16 institutional investors that purchased Actuate Therapeutics' stock in the last 24 months, the following investors and hedge funds have bought the highest volume of shares: BIOS Capital Management LP ($9.97M), Voss Capital LP ($286.14K), Geode Capital Management LLC ($84.56K), Northwestern University ($27.78K), Sigma Planning Corp ($23.68K), Goldman Sachs Group Inc. ($22.21K), and Gleason Group Inc. ($19.03K). How much institutional buying is happening at Actuate Therapeutics? Institutional investors have bought a total of 10,545,371 shares in the last 24 months. This purchase volume represents approximately $83.10M in transactions. Related Companies TRML Institutional Ownership PRME Institutional Ownership BCYC Institutional Ownership ARVN Institutional Ownership KURA Institutional Ownership TBPH Institutional Ownership SAGE Institutional Ownership ORKA Institutional Ownership RAPP Institutional Ownership SLDB Institutional Ownership This page (NASDAQ:ACTU) was last updated on 8/14/2025 by MarketBeat.com Staff From Our PartnersGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredBREAKING: The House just passed 3 pro-crypto bills!THREE pro-crypto bills just passed the House! Now, experts believe altcoin season is officially here. Crypto 101 Media | SponsoredGet This Stock NowThis company is the lifeblood of AI data centers, yet almost no one has caught up with the story. Their hardwa...InvestorPlace | SponsoredGenerate up to $5,000/month with 10X less money?The secret to retiring without a million-dollar nest egg. I'm talking about generating enough monthly inco...Investors Alley | SponsoredBig Changes Coming in August — Is Your IRA Ready?Banks aren’t waiting for the headlines to catch up. They’ve already started moving their wealth out of pape...Reagan Gold Group | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredAmazon’s big Bitcoin embarrassmentBitcoin just passed Amazon in total market cap — but most investors are missing the bigger opportunity. Whi...Brownstone Research | SponsoredHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Actuate Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Actuate Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access